RT Journal Article
SR Electronic
T1 Argentine Registry of neurological manifestations due to coronavirus-19 (COVID-19)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253558
DO 10.1101/2021.03.19.21253558
A1 Lucas Alessandro
A1 Franco Appiani
A1 Mariana Bendersky
A1 Brenda Borrego Guerrero
A1 Guadalupe Bruera
A1 Patricia Cairola
A1 Ismael Calandri
A1 Juan Martín Cardozo Oliver
A1 María Emilia Clément
A1 Marianna Di Egidio
A1 José Luis Di Pace
A1 Melina Diaconchuk
A1 Celeste Esliman
A1 Ma Martha Esnaola y Rojas
A1 Julián Fernández Boccazzi
A1 Andrea Fabiana Franco
A1 Gisella Gargiulo
A1 Daniela Laura Giardino
A1 César Gómez
A1 Ana Karina Guevara
A1 Natalia Gutierrez
A1 Javier Hryb
A1 Ibarra Viviana
A1 Franco Janota
A1 Mabel Laserna
A1 Luis Alfredo Larcher
A1 Fernando Leone
A1 Geraldine Luetic
A1 Claudia Andrea Medina
A1 María Laura Menichini
A1 Gonzalo Nieto
A1 María Fernanda Páez
A1 Francisco Peñalver
A1 Mónica Perassolo
A1 Gabriel Persi
A1 Claudia Pestchanker
A1 Oscar Porta
A1 Roberto Daniel Rey
A1 Gabriel Eduardo Rodríguez
A1 Marina Romano
A1 Marcelo Rugiero
A1 Patricia Saidón
A1 María Florencia Sica
A1 Erica Stankievich
A1 Adriana Tarulla
A1 Guillermo Zalazar
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.19.21253558.abstract
AB COVID-19 disease has spread around the world since December 2019. Neurological symptoms are part of its clinical spectrum.Objective To know the neurological manifestations in patients infected by COVID-19 in Argentina.Methods Multicenter study conducted in adults, from May 2020 to January 2021, with confirmed COVID-19 and neurological symptoms. Demographic variables, existence of systemic or neurological comorbidities, the form of onset of the infection, alteration in complementary studies and the degree of severity of neurological symptoms were recorded.Results 817 patients from all over the country were included, 52% male, mean age 38 years, most of them without comorbidities or previous neurological pathology. The first symptom of the infection was neurological in 56.2% of the cases, predominantly headache (69%), then anosmia / ageusia (66%). Myalgias (52%), allodynia / hyperalgesia (18%), and asthenia (6%) were also reported. 3.2% showed diffuse CNS involvement such as encephalopathy or seizures. 1.7% had cerebrovascular complications. Sleep disorders were observed in 3.2%. 6 patients were reported with Guillain Barré (GBS), peripheral neuropathy (3.4%), tongue paresthesia (0.6%), hearing loss (0.4%), plexopathy (0.3%). The severity of neurological symptoms was correlated with age and the existence of comorbidities.Conclusions Our results, similar to those of other countries, show two types of neurological symptoms associated with COVID-19: some potentially disabling or fatal such as GBS or encephalitis, and others less devastating, but more frequent such as headache or anosmia that demand increasingly long-term care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was evaluated and approved by the research ethics committees of each participating unit: -Instituto Argentino de Investigaciones Neurologicas -Hospital Ramos Mejia -Hospital Durand -Hospital Fernandez _Hospital Privado de la Comunidad _Hospital Universitario CEMIC -Hospital de San Juan -Hospital Italiano de Buenos Aires -Sanatorio Trinidad Mitre -Sanatorio Las Lomas -Instituto Milstein -Hospital Privado de Rosario -Instituto Max Planck -Hospital Enrique Vera Barros -Sanatorio Dr Julio Mendez -Hospital Muniz -Hospital Tornu -Hospital Pinero -Sanatorio Finochietto -Sanatorio del Norte -Centro medico Roca -Hospital Bernardino Rivadavia -Instituto de Neurociencias de RosarioAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred in the manuscript are available upon request